PepGen Inc. (PEPG)
3.84
-0.09
(-2.29%)
USD |
NASDAQ |
Nov 20, 10:35
PepGen Cash from Operations (Quarterly) : -13.18M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -13.18M |
| June 30, 2026 | -15.81M |
| March 31, 2026 | -18.43M |
| December 31, 2025 | -15.84M |
| September 30, 2025 | -19.26M |
| June 30, 2025 | -23.60M |
| March 31, 2025 | -22.93M |
| December 31, 2024 | -19.48M |
| September 30, 2024 | -24.01M |
| June 30, 2024 | -16.35M |
| March 31, 2024 | -22.53M |
| December 31, 2023 | -19.42M |
| Date | Value |
|---|---|
| September 30, 2023 | -16.48M |
| June 30, 2023 | -17.68M |
| March 31, 2023 | -15.42M |
| December 31, 2022 | -13.39M |
| September 30, 2022 | -20.97M |
| June 30, 2022 | -12.64M |
| March 31, 2022 | -12.27M |
| December 31, 2021 | -5.986M |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | -2.83M |
| December 31, 2020 | -0.088M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Korsana Biosciences, Inc. | -46.83M |
| IRulya Therapeutics, Inc. | -9.84M |
| Q32 Bio, Inc. | -4.418M |
| Bridgebio Oncology Therapeutics, Inc. | -28.36M |
| Oncolytics Biotech, Inc. | -6.754M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 12.46M |
| Cash from Financing (Quarterly) | -0.086M |
| Free Cash Flow | -63.28M |
| Free Cash Flow Per Share (Quarterly) | -0.1902 |
| Free Cash Flow to Equity (Quarterly) | -12.69M |
| Free Cash Flow to Firm (Quarterly) | -13.18M |
| Free Cash Flow Yield | -23.79% |